Christopher Peetz Net Worth

The estimated Net Worth of Christopher Peetz is at least $12.2 Milhão dollars as of 23 July 2024. Mr. Peetz owns over 34,013 units of Mirum Pharmaceuticals Inc stock worth over $5,313,476 and over the last 7 years he sold MIRM stock worth over $640,937. In addition, he makes $6,235,180 as President, Chief Executive Officer, e Director at Mirum Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Peetz MIRM stock SEC Form 4 insiders trading

Christopher has made over 10 trades of the Mirum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 34,013 units of MIRM stock worth $99,998 on 23 July 2024.

The largest trade he's ever made was exercising 34,013 units of Mirum Pharmaceuticals Inc stock on 23 July 2024 worth over $99,998. On average, Christopher trades about 2,846 units every 61 days since 2018. As of 23 July 2024 he still owns at least 126,783 units of Mirum Pharmaceuticals Inc stock.

You can see the complete history of Mr. Peetz stock trades at the bottom of the page.

Christopher Peetz biography

Christopher Peetz was President, Director of the Company. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier Healthcare Partners (“Frazier”), a private equity and venture capital firm, since May 2017. Prior to joining our company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc. (“Flashlight”), a biotechnology company. He served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc. (“Tobira”), a publicly-traded biotechnology company acquired by Allergan plc (“Allergan”), a public pharmaceutical company, in November 2016, from May 2014 to December 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics (“Jennerex”), a biopharmaceutical company. Prior to Jennerex, Mr. Peetz held various positions at Onyx, including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He has also served as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, since April 2018. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.

What is the salary of Christopher Peetz?

As the President, Chief Executive Officer, e Director of Mirum Pharmaceuticals Inc, the total compensation of Christopher Peetz at Mirum Pharmaceuticals Inc is $6,235,180. There are no executives at Mirum Pharmaceuticals Inc getting paid more.

How old is Christopher Peetz?

Christopher Peetz is 41, he's been the President, Chief Executive Officer, e Director of Mirum Pharmaceuticals Inc since 2019. There are 19 older and no younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.

What's Christopher Peetz's mailing address?

Christopher's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY, CA, 94404.

Insiders trading at Mirum Pharmaceuticals Inc

Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.

What does Mirum Pharmaceuticals Inc do?

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Complete history of Mr. Peetz stock trades at Alpine Immune Sciences Inc e Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc executives and stock owners

Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Christopher Peetz,
  President, Chief Executive Officer, Director
• Michael Grey,
  Chairman of the Board
• Lara Longpre,
  Chief Development Officer
• Pamela Vig,
  Chief Scientific Officer
• Christopher Peetz,
  Pres, CEO & Director
• Dr. Ian Clements,
  Chief Financial Officer
• Peter Radovich M.B.A., Ph.D.,
  Chief Operating Officer
• Laurent Fischer,
  Independent Director
• Laura Brege,
  Independent Director
• Niall ODonnell,
  Independent Director
• Edward Mathers,
  Independent Director
• Patrick Heron,
  Independent Director
• Tiba Aynechi,
  Director
• Edwin Tucker,
  Chief Medical Officer
• Ian Clements,
  Chief Financial Officer
• Vinita P. Kumar,
  Sr. vice Pres of Quality
• Lara Longpre MBA, MSC,
  Chief Devel. Officer
• Dr. Pamela Vig Ph.D.,
  Head of R&D
• Erin Campany,
  Sr. VP of HR
• Dr. Edwin Jonathan Tucker M.D.,
  Chief Medical Officer
• Paul K. Ross,
  Chief Compliance Officer
• Lara Longpre MSC, MBA,
  Chief Devel. Officer
• Carol L Brosgart,
  Director
• Holdings A/S Novo,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Niall O'donnell,
  Director
• Peter W. Sonsini,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ali Behbahani,
  10% owner
• Forest Baskett,
  10% owner
• Joshua Makower,
  10% owner
• David M Mott,
  10% owner
• Paul Edward Walker,
  10% owner
• Life Sciences Ix, L.P.Fhmls...,
  
• Carmen Chang,
  10% owner
• Scott D Sandell,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• James E Deerfield Mgmt Hif,...,
  
• Enterprise Associates 16, L...,
  10% owner
• William Fairey,
  
• Timothy P Walbert,
  
• Joanne Quan,
  CHIEF MEDICAL OFFICER
• Saira Ramasastry,
  
• James E Deerfield Mgmt Hif,...,
  
• Lon Cardon,
  
• Partners 16, L.P.Nea 16 Gp,...,
  
• Jolanda Howe,
  SVP, GLOBAL CONTROLLER
• Eric Bjerkholt,
  CHIEF FINANCIAL OFFICER
• Peter Radovich,
  PRESIDENT AND COO